-
Je něco špatně v tomto záznamu ?
The effect of aldose reductase inhibition by JMC-2004 on hyperglycemia-induced endothelial dysfunction
I Papezikova, M Pekarova, M Chatzopoulou, I Nicolaou, V Demopoulos, L Kubala, A Lojek
Jazyk angličtina Země Švédsko
Typ dokumentu práce podpořená grantem
- MeSH
- aldehydreduktasa antagonisté a inhibitory MeSH
- buněčné linie MeSH
- calcimycin farmakologie MeSH
- cévní endotel patologie účinky léků MeSH
- elektrochemie MeSH
- endoteliální buňky patologie účinky léků MeSH
- fenoly farmakologie MeSH
- glukosa farmakologie MeSH
- glyceraldehyd metabolismus MeSH
- hydroxylový radikál metabolismus MeSH
- hyperglykemie patologie MeSH
- inhibitory enzymů farmakologie MeSH
- luminiscence MeSH
- oxid dusnatý metabolismus MeSH
- peroxidy metabolismus MeSH
- pyrroly farmakologie MeSH
- skot MeSH
- synthasa oxidu dusnatého, typ III metabolismus MeSH
- western blotting MeSH
- zvířata MeSH
- Check Tag
- skot MeSH
- zvířata MeSH
- Publikační typ
- práce podpořená grantem MeSH
OBJECTIVES: An increased glucose utilization by aldose reductase (ALR-2) has been implicated in the pathogenesis of diabetic vascular complications. In this process, several mechanisms are involved, including the depletion of cofactors required for the action of antioxidant enzymes or endothelial NO synthase. In this study, the effect of a novel ALR-2 inhibitor JMC-2004 on hyperglycemia-induced endothelial dysfunction was studied. METHODS: Bovine aortic endothelial cells (BAEC) were treated with glucose (30 mM), JMC-2004 (0.01mM), or glucose and JMC-2004 for 24 h. The cells were then stimulated with calcium ionophore A23187 after which NO production was measured electrochemically using a porphyrine-coated carbon NO electrode. Nitrite concentrations were determined in the cell supernatants. The peroxyl and hydroxyl radical-scavenging activity of JMC-2004 was measured with luminol-enhanced chemiluminescence. The expression of eNOS was determined by Western blotting. JMC-2004 IC50 for ALR-2 was determined colorimetrically with D-glyceraldehyde as a substrate. RESULTS: Incubating the cells with 30 mM glucose strongly diminished A23187- induced NO production. Treatment with JMC-2004 restored NO production by 40% without affecting eNOS expression. This effect was probably antioxidantindependent, since JMC-2004 did not have any antioxidant capacity. JMC-2004 exerted high selectivity towards ALR-2. CONCLUSIONS: ALR-2 inhibition with JMC-2004 was able to abolish hyperglycemia- induced endothelial dysfunction in bovine aortic endothelial cells.
- 000
- 02525naa 2200541 a 4500
- 001
- bmc11006273
- 003
- CZ-PrNML
- 005
- 20120907082855.0
- 008
- 110401s2008 sw e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sw
- 100 1_
- $a Papežíková, Ivana $7 xx0098961
- 245 14
- $a The effect of aldose reductase inhibition by JMC-2004 on hyperglycemia-induced endothelial dysfunction / $c I Papezikova, M Pekarova, M Chatzopoulou, I Nicolaou, V Demopoulos, L Kubala, A Lojek
- 314 __
- $a Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic. ivanah@ibp.cz
- 520 9_
- $a OBJECTIVES: An increased glucose utilization by aldose reductase (ALR-2) has been implicated in the pathogenesis of diabetic vascular complications. In this process, several mechanisms are involved, including the depletion of cofactors required for the action of antioxidant enzymes or endothelial NO synthase. In this study, the effect of a novel ALR-2 inhibitor JMC-2004 on hyperglycemia-induced endothelial dysfunction was studied. METHODS: Bovine aortic endothelial cells (BAEC) were treated with glucose (30 mM), JMC-2004 (0.01mM), or glucose and JMC-2004 for 24 h. The cells were then stimulated with calcium ionophore A23187 after which NO production was measured electrochemically using a porphyrine-coated carbon NO electrode. Nitrite concentrations were determined in the cell supernatants. The peroxyl and hydroxyl radical-scavenging activity of JMC-2004 was measured with luminol-enhanced chemiluminescence. The expression of eNOS was determined by Western blotting. JMC-2004 IC50 for ALR-2 was determined colorimetrically with D-glyceraldehyde as a substrate. RESULTS: Incubating the cells with 30 mM glucose strongly diminished A23187- induced NO production. Treatment with JMC-2004 restored NO production by 40% without affecting eNOS expression. This effect was probably antioxidantindependent, since JMC-2004 did not have any antioxidant capacity. JMC-2004 exerted high selectivity towards ALR-2. CONCLUSIONS: ALR-2 inhibition with JMC-2004 was able to abolish hyperglycemia- induced endothelial dysfunction in bovine aortic endothelial cells.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a aldehydreduktasa $x antagonisté a inhibitory $7 D000449
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a western blotting $7 D015153
- 650 _2
- $a calcimycin $x farmakologie $7 D000001
- 650 _2
- $a skot $7 D002417
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a elektrochemie $7 D004563
- 650 _2
- $a endoteliální buňky $x patologie $x účinky léků $7 D042783
- 650 _2
- $a cévní endotel $x patologie $x účinky léků $7 D004730
- 650 _2
- $a inhibitory enzymů $x farmakologie $7 D004791
- 650 _2
- $a glukosa $x farmakologie $7 D005947
- 650 _2
- $a glyceraldehyd $x metabolismus $7 D005985
- 650 _2
- $a hydroxylový radikál $x metabolismus $7 D017665
- 650 _2
- $a hyperglykemie $x patologie $7 D006943
- 650 _2
- $a luminiscence $7 D049449
- 650 _2
- $a oxid dusnatý $x metabolismus $7 D009569
- 650 _2
- $a synthasa oxidu dusnatého, typ III $x metabolismus $7 D052250
- 650 _2
- $a peroxidy $x metabolismus $7 D010545
- 650 _2
- $a fenoly $x farmakologie $7 D010636
- 650 _2
- $a pyrroly $x farmakologie $7 D011758
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pekarová, Michaela, $d 1982-2019 $7 mub2011659519
- 700 1_
- $a Chatzopoulou, Maria
- 700 1_
- $a Nicolaou, Ioannis
- 700 1_
- $a Demopoulos, Vassilis
- 700 1_
- $a Kubala, Lukáš, $d 1973- $7 xx0094314
- 700 1_
- $a Lojek, Antonín, $d 1954- $7 xx0063943
- 773 0_
- $t Neuroendocrinology Letters $g Roč. 29, č. 5 (2008), s. 775-778 $x 0172-780X $w MED00168352
- 910 __
- $a ABA008 $b x $y 2
- 990 __
- $a 20110414101644 $b ABA008
- 991 __
- $a 20120907083026 $b ABA008
- 999 __
- $a ok $b bmc $g 833879 $s 698367
- BAS __
- $a 3
- BMC __
- $a 2008 $b 29 $c 5 $d 775-778 $i 0172-780X $m Neuro-endocrinology letters $n Neuro-endocrinol. lett. $x MED00168352
- LZP __
- $a 2011-1B09/dkjt